FR22C1037I2 - Procedes de glycoconjugaison et compositions - Google Patents

Procedes de glycoconjugaison et compositions

Info

Publication number
FR22C1037I2
FR22C1037I2 FR22C1037C FR22C1037C FR22C1037I2 FR 22C1037 I2 FR22C1037 I2 FR 22C1037I2 FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 I2 FR22C1037 I2 FR 22C1037I2
Authority
FR
France
Prior art keywords
glycoconjugation
compositions
methods
glycoconjugation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1037C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of FR22C1037I1 publication Critical patent/FR22C1037I1/fr
Application granted granted Critical
Publication of FR22C1037I2 publication Critical patent/FR22C1037I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR22C1037C 2012-08-16 2022-07-28 Procedes de glycoconjugaison et compositions Active FR22C1037I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
PCT/IB2013/056597 WO2014027302A1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Publications (2)

Publication Number Publication Date
FR22C1037I1 FR22C1037I1 (fr) 2022-09-09
FR22C1037I2 true FR22C1037I2 (fr) 2023-05-26

Family

ID=49385307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1037C Active FR22C1037I2 (fr) 2012-08-16 2022-07-28 Procedes de glycoconjugaison et compositions

Country Status (32)

Country Link
US (6) US9517274B2 (en:Method)
EP (2) EP2885007B1 (en:Method)
JP (1) JP6291495B2 (en:Method)
KR (1) KR101742406B1 (en:Method)
CN (1) CN104661684B (en:Method)
AR (1) AR092368A1 (en:Method)
AU (1) AU2013303826B2 (en:Method)
BR (1) BR112015003227B1 (en:Method)
CA (1) CA2881420C (en:Method)
DK (2) DK3421051T3 (en:Method)
ES (2) ES2700824T3 (en:Method)
FI (1) FIC20220032I1 (en:Method)
FR (1) FR22C1037I2 (en:Method)
HU (3) HUE049531T2 (en:Method)
IL (1) IL237066B (en:Method)
IN (1) IN2015DN00694A (en:Method)
LU (1) LUC00273I2 (en:Method)
MX (1) MX363511B (en:Method)
MY (1) MY167579A (en:Method)
NL (1) NL301188I2 (en:Method)
NO (1) NO2022034I1 (en:Method)
NZ (1) NZ704490A (en:Method)
PE (1) PE20150464A1 (en:Method)
PH (1) PH12015500243B1 (en:Method)
PL (2) PL2885007T3 (en:Method)
PT (2) PT3421051T (en:Method)
RU (2) RU2645071C2 (en:Method)
SA (1) SA515360035B1 (en:Method)
SG (1) SG11201500566XA (en:Method)
SI (2) SI2885007T1 (en:Method)
TW (1) TWI480049B (en:Method)
WO (1) WO2014027302A1 (en:Method)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3421051T (pt) 2012-08-16 2020-06-26 Pfizer Processos e composições de glicoconjugação
EP3096786B1 (en) * 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN112168957A (zh) * 2014-01-21 2021-01-05 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
CN106103461B (zh) 2014-03-13 2019-05-10 巴塞尔大学 结合抗髓鞘相关糖蛋白的IgM抗体的碳水化合物配体
ES2945312T3 (es) 2015-01-15 2023-06-30 Pfizer Composiciones inmunogénicas para su uso en vacunas antineumocócicas
CN107624070A (zh) * 2015-05-04 2018-01-23 辉瑞大药厂 B族链球菌多糖‑蛋白质缀合物、制造缀合物的方法、含缀合物的免疫原性组合物及其用途
AU2016276269B2 (en) * 2015-06-08 2021-01-28 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017085586A1 (en) * 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MY199342A (en) 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
PH12019500399B1 (en) 2016-09-02 2024-05-15 Sanofi Pasteur Inc Neisseria meningitidis vaccine
BR112019013475A2 (pt) 2016-12-30 2020-02-27 Sutrovax, Inc. Conjugados de polipeptídeo-antígeno com aminoácidos não naturais
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
KR102634811B1 (ko) 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2020533437A (ja) 2017-09-07 2020-11-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 肺炎球菌多糖体および免疫原性多糖体−キャリアタンパク質コンジュゲートでのその使用
KR20250004911A (ko) 2017-09-07 2025-01-08 머크 샤프 앤드 돔 엘엘씨 담체 단백질에의 접합을 위한 폐렴구균 폴리사카라이드의 제제화 방법
IL276229B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
CN111757753B (zh) 2018-02-05 2024-08-20 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
RU2020131305A (ru) * 2018-03-23 2022-04-26 Коранекс Кэпитал Прецизионные гликоконъюгаты в качестве терапевтических инструментов
AU2019256218A1 (en) 2018-04-18 2020-12-03 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (zh) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
US20250281601A1 (en) 2021-05-03 2025-09-11 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998056942A1 (en) 1997-06-12 1998-12-17 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
CN1197618C (zh) 1998-09-30 2005-04-20 惠氏控股有限公司 突变霍乱全毒素佐剂
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
ES2388848T3 (es) * 2001-01-23 2012-10-19 Sanofi Pasteur Inc. Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína
KR100877258B1 (ko) 2001-06-07 2009-01-12 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
US6995001B2 (en) * 2002-10-03 2006-02-07 Wyeth Holdings Corporation Processing for preparing monoprotected diols from symmetric diols
US9296795B2 (en) * 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE410431T1 (de) * 2004-04-14 2008-10-15 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
PT1868645E (pt) 2005-04-08 2012-05-17 Wyeth Llc Composição conjugada de polissacárido-proteína pneumocócica polivalente
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
SI1973564T1 (sl) * 2005-12-22 2017-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega konjugate kapsularnih polisaharidov Streptococcusa pneumoniae
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
BRPI0708562A2 (pt) * 2006-03-07 2011-06-07 Wyeth Corp processos para preparar conjugados de polietileno glicor de macrolìdeos imunossupressores, um macrolìdeo imunossupressor peguilado, uma rapamicina peguilada, um everolimus peguilado, um cci-779 peguilado e um tacrolimus peguilado, e, produto
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
DE102006026436A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности
TWI505834B (zh) 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
CA2766614C (en) * 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
EP2503995B1 (en) * 2009-11-24 2017-11-01 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits
BR112013012626A2 (pt) * 2010-12-10 2016-07-19 Merck Sharp & Dohme formulação, composição imunogênica, e, seringa pré-carregada
ES2686927T3 (es) * 2011-09-07 2018-10-22 Prolynx Llc Hidrogeles con reticulación biodegradable
PT3421051T (pt) * 2012-08-16 2020-06-26 Pfizer Processos e composições de glicoconjugação
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates

Also Published As

Publication number Publication date
AR092368A1 (es) 2015-04-15
JP6291495B2 (ja) 2018-03-14
US20200246448A1 (en) 2020-08-06
KR20150041139A (ko) 2015-04-15
US11723965B2 (en) 2023-08-15
NZ704490A (en) 2017-07-28
CA2881420A1 (en) 2014-02-20
EP3421051B1 (en) 2020-05-13
US20180221467A1 (en) 2018-08-09
PH12015500243B1 (en) 2019-05-31
PH12015500243A1 (en) 2015-03-30
LUC00273I2 (en:Method) 2025-05-12
RU2724840C2 (ru) 2020-06-25
PE20150464A1 (es) 2015-04-25
IN2015DN00694A (en:Method) 2015-06-26
NO2022034I1 (no) 2022-08-04
SI2885007T1 (sl) 2018-12-31
AU2013303826B2 (en) 2017-06-29
US20150216996A1 (en) 2015-08-06
JP2015524839A (ja) 2015-08-27
DK2885007T3 (en) 2018-12-03
PL3421051T3 (pl) 2020-10-05
EP3421051A1 (en) 2019-01-02
TW201420115A (zh) 2014-06-01
WO2014027302A1 (en) 2014-02-20
HUS2200034I1 (hu) 2022-08-28
BR112015003227A2 (pt) 2017-07-04
FIC20220032I1 (fi) 2022-08-05
SI3421051T1 (sl) 2020-08-31
US10583187B2 (en) 2020-03-10
SG11201500566XA (en) 2015-04-29
RU2016136630A (ru) 2018-12-11
US9517274B2 (en) 2016-12-13
ES2700824T3 (es) 2019-02-19
RU2015103017A (ru) 2016-10-10
US20170224804A1 (en) 2017-08-10
CN104661684B (zh) 2018-03-20
PT2885007T (pt) 2018-12-10
SA515360035B1 (ar) 2015-09-15
US11110160B2 (en) 2021-09-07
TWI480049B (zh) 2015-04-11
BR112015003227B1 (pt) 2020-10-27
IL237066B (en) 2019-03-31
MX363511B (es) 2019-03-26
CN104661684A (zh) 2015-05-27
RU2645071C2 (ru) 2018-02-15
US20220096619A1 (en) 2022-03-31
US20230355735A1 (en) 2023-11-09
HUE041381T2 (hu) 2019-05-28
CA2881420C (en) 2016-11-15
FR22C1037I1 (fr) 2022-09-09
DK3421051T3 (da) 2020-06-22
MY167579A (en) 2018-09-20
HUE049531T2 (hu) 2020-10-28
PT3421051T (pt) 2020-06-26
PL2885007T3 (pl) 2019-02-28
US9950054B2 (en) 2018-04-24
RU2016136630A3 (en:Method) 2019-12-30
HK1210021A1 (en) 2016-04-15
AU2013303826A1 (en) 2015-02-12
MX2015001992A (es) 2015-10-05
ES2800479T3 (es) 2020-12-30
EP2885007B1 (en) 2018-10-10
KR101742406B1 (ko) 2017-05-31
EP2885007A1 (en) 2015-06-24
NL301188I2 (nl) 2024-05-15

Similar Documents

Publication Publication Date Title
FR22C1037I2 (fr) Procedes de glycoconjugaison et compositions
DK2935299T3 (da) Glycokonjugationsfremgangsmåde
IL261264B (en) Purification of iduronate-2 sulfatase
PT3725778T (pt) Formulações de enzalutamida
SMT202100154T1 (it) Composizioni e metodi per identificare precisamente mutazioni
EP2876220A4 (en) DREDGING
DK3187586T3 (da) Inducerbar co-ekspressionssystem
PT2836588T (pt) Bioproteção usando estirpes de lactobacilo paracasei
BR112014032798A2 (pt) composição
BR112015001562A2 (pt) biotinas e composições
ME03413B (me) Kompozicije које sadrže peg i askorbat
EP2878951A4 (en) ANALYTICAL DEVICE
BR112014020547A2 (pt) composições oleosas e métodos de produção
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
IT1402519B1 (it) Manichino migliorato
EP2878228A4 (en) EASEL
BR112014032712A2 (pt) composição
HUE049445T2 (hu) Új kompozíciók
DK2811828T3 (da) Adjuvanssammensætninger
EP2837670A4 (en) Fluorobiphenyl-containing composition
EP2823074A4 (en) NICKEL-ALUMINUM-zirconium alloys
CO7071132A2 (es) Composiciones de acción prolongada
DK2800573T3 (da) Oftalmologisk sammensætning
EP2877065A4 (en) MANNEQUIN
UA22863S (uk) Агрегат ґрунтообробний